Use of Plerixafor for Stem Cell Mobilization in the Setting of Autologous and Allogeneic Stem Cell Transplantations: An Update

Figures & data

Figure 1 Strategies for stem cell mobilization in practice. Possible strategies in stem cell mobilization: with G-CSF only (A), with chemotherapy (B), in healthy donors (C).

Abbreviation: G-CSF, granulocyte colony-stimulating factor.

Figure 2 Approaches for use of plerixafor in patients with (predicted) mobilization failure. Approaches for the use of plerixafor: after mobilization failure with G-CSF (A), in patients with high-risk for mobilization failure with G-CSF (B), in patients with mobilization failure with G-CSF and plerixafor (C).

Abbreviation: G-CSF, granulocyte colony-stimulating factor.

Table 1 Studies with Plerixafor for Allogeneic Stem Cell Transplantation

Author/Year	No. Donors	Transplantation Setting	Mobilization Setting	Plerixafor Dose	CD34+ in PB After 1 Gift Plerixafor (Median; x10^9/L)	Failure After 1 Gift Plerixafor	Total CD34+ Collected (Median; x10^6/kg)
Devine/2008^Citation60	25	HLA-identical siblings	Upfront	0.24 mg/kg sc	16	33%	2.9
Hauge/2014^Citation61	6	Haplo-identical (n=4)/HLA-identical (n=2) donors	Pre-emptive	0.24 mg/kg sc	Too small sample size	None	Too small sample size
Gattilo/2015^Citation62	10	Haplo-identical (n=8)/HLA-identical (n=2) donors	Pre-emptive (n=8)/contraindication to G-CSF (n=2)	0.35 mg/kg sc	41	Not documented	2.8
Fiala/2016^Citation63	32	Not documented	Remobilization	Not documented	30	None	7.1
Schroeder/2017^Citation64	21	HLA-identical siblings	Upfront, Phase 1	0.24 mg/kg sc	Not documented	33%	3.5
Schroeder/2017^Citation64	29	HLA-identical siblings	Upfront, Phase 2	0.32 mg/kg iv	Not documented	34%	2.9
Jaiswal/2017^Citation65	26	Haplo-identical donors	Pre-emptive	0.24 mg/kg sc	136	0%	2.7
de Greef/2019^Citation66	23	HLA-identical siblings	Upfront	0.32 mg/kg sc	26	48%	3.3
Chen/2019^Citation67	64	HLA-identical siblings	Upfront	0.24 mg/kg sc	19	30%	4.7
Holig/2021^Citation68	37	HLA-identical donors	Pre-emptive	0.24 mg/kg sc	44	43%	3.7
Cid/2021^Citation69	30	HLA-identical donors	Pre-emptive	0.24 mg/kg sc	55	17%	4.2

Abbreviations: HLA, human leukocyte antigen; G-CSF, granulocyte colony-stimulating factor; sc, subcutaneous; iv, intravenous; PB, peripheral blood.

Devine SM, Vij R, Rettig M, et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood. 2008;112(4):990–998. doi:10.1182/blood-2007-12-130179.

 PubMed Web of Science ®Google Scholar

Hauge AW, Haastrup EK, Sengeløv H, Minulescu L, Dickmeiss E, Fischer-Nielsen A. Addition of plerixafor for CD34+ cell mobilization in six healthy stem cell donors ensured satisfactory grafts for transplantation. Transfusion. 2014;54(4):1055–1058. doi:10.1111/trf.12383.

 PubMed Web of Science ®Google Scholar

Gattillo S, Marktel S, Rizzo L, et al. Plerixafor on demand in ten healthy family donors as a rescue strategy to achieve an adequate graft for stem cell transplantation. Transfusion. 2015;55(8):1993–2000. doi:10.1111/trf.13059.

 Web of Science ®Google Scholar

Fiala MA, Park S, Slade M, DiPersio JF, Stockerl-Goldstein KE. Remobilization of hematopoietic stem cells in healthy donors for allogeneic transplantation. Transfusion. 2016;56(9):2331–2335. doi:10.1111/trf.13688.

 Web of Science ®Google Scholar

Schroeder MA, Rettig MP, Lopez S, et al. Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft. Blood. 2017;129(19):2680–2692. doi:10.1182/blood-2016-09-739722.

 PubMed Web of Science ®Google Scholar

Jaiswal SR, Bhakuni P, Joy A, et al. Impact of single-dose plerixafor as an adjunct to granulocyte colony-stimulating factor-based peripheral blood stem cell mobilization on the graft composition and outcome for T cell-replete haploidentical peripheral blood stem cell transplantation with post-transplantation cyclophosphamide: a comparative study. Biol Blood Marrow Transplant. 2018;24(3):542–548. doi:10.1016/j.bbmt.2017.11.014.

 PubMed Web of Science ®Google Scholar

de Greef GE, Braakman E, van der Holt B, et al. The feasibility and efficacy of subcutaneous plerixafor for mobilization of peripheral blood stem cells in allogeneic HLA-identical sibling donors: results of the HOVON-107 study. Transfusion. 2019;59(1):316–324. doi:10.1111/trf.15037.

 Web of Science ®Google Scholar

Chen YB, Le-rademacher J, Brazauskas R, et al. Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells. Blood Adv. 2019;3(6):875–883. doi:10.1182/bloodadvances.2018027599.

 PubMed Web of Science ®Google Scholar

Holig K, Schmidt H, Hutter G, et al. Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective Phase II-trial. Bone Marrow Transplant. 2021;56(3):635–645. doi:10.1038/s41409-020-01053-4.

 Web of Science ®Google Scholar

Cid J, Monsalvo S, Castillo C, et al. Addition of plerixafor to G-CSF in poor mobilizing healthy related donors overcame mobilization failure: an observational case series on behalf of the Grupo Espanol de Trasplante Hematopoyetico (GETH). Transfus Apher Sci. 2021;60(2):103052. doi:10.1016/j.transci.2021.103052.

 Web of Science ®Google Scholar